<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862223</url>
  </required_header>
  <id_info>
    <org_study_id>AAME1000</org_study_id>
    <nct_id>NCT02862223</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Effects of Neprinol Study Product on Vascular Function</brief_title>
  <official_title>Neprinol for Cardiovascular Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arthur Andrew Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Synergize Inc.</source>
  <brief_summary>
    <textblock>
      This open-label study investigated the effectiveness of Neprinol on maintaining healthy
      cardiovascular health in overweight and obese adults. Subjects took 3 capsules, 3 times per
      day over a period of 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in levels of D-Dimer after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of Fibrinogen after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of PAI-1 after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of Fibrin Monomer after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of Thrombin anti-thrombin III after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of ESR after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of PTT after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of PT-INR after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of Activated Clotting Time after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of Platelet Count after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in Whole Blood Viscosity after 12 weeks of supplementation with the study</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in circulatory function after 12 weeks of supplementation with the study product, measured by EndoPAT analysis</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in blood pressure after 12 weeks of supplementation with the study</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in levels of HS-CRP after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in levels of Adiponectin after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in levels of IL-6 after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in inflammatory markers after 12 weeks of supplementation with Neprinol. Inflammatory markers: HS-CRP, Adiponectin, IL-6, TNF-alpha, VEGF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in levels of VEGF after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in levels of TNF-alpha after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in NK Cell Cytotoxicity after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in lipid levels after 12 weeks of supplementation with the study product, measured as LDL, HDL and TG</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Glucose AUC after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The change in CBC levels after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number of Adverse Events reported after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Neoprinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Neoprinol</intervention_name>
    <arm_group_label>Neoprinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female ≥ 18 and ≤ 75 years of age.

          -  Overweight subjects (BMI ≥ 27 and &lt; 30) and Obese subjects (BMI &gt; 30 and ≤ 35)

          -  Subjects with elevated cholesterol.

               -  Total cholesterol 240 mg/dL.

          -  Subjects with elevated inflammation

               -  HS-CRP ≥ 3 mg/L.

          -  Judged by the Investigator to be in general good health on the basis of medical
             history.

          -  Females of child bearing potential must agree to use appropriate birth control methods
             during the entire study period.

          -  Agree not to initiate any new exercise or diet programs during the entire study
             period.

          -  Agree not to change their current diet or exercise program during the entire study
             period.

          -  Understands the study procedures and signs forms providing informed consent to
             participate in the study and authorization for release of relevant protected health
             information to the study investigator.

        Exclusion Criteria:

          -  Subjects with a history of congestive heart failure (any classification), unstable
             angina, or acute coronary syndrome within the past 30 days.

          -  Uncontrolled hypertension (blood pressure ≥ 170/100 mm Hg)

          -  Subjects with a history of gastrointestinal disease or surgery affecting absorption

          -  Subjects with peripheral arterial disease

          -  Daily use of NSAIDs, however 81mg of aspirin daily for cardio protection is allowed

          -  Daily use of anti-inflammatory or omega-3-fatty acid dietary supplements

               -  2 week washout is allowed

          -  Use of any immunosuppressive drugs in the last 12 months (including steroids or
             biologics)

          -  Any significant GI condition that would severely interfere with the evaluation of the
             study product including but not limited to inflammatory bowel disease (Ulcerative
             Colitis or Chron's), history of frequent diarrhea, history of surgery for weight loss
             (including gastric bypass or lapband), history of perforation of the stomach or
             intestines, gastroparesis, clinically important lactose intolerance

          -  Subjects with a history of using diabetic medications during the prior 4 weeks to
             study start

          -  Subjects with a history of using insulin during prior 12 weeks to study start.

          -  Any active infection, or infection in the last month requiring antibiotics, anti-viral
             medication, or hospitalization

          -  History or presence of cancer in the prior two years, except for non-melanoma skin
             cancer.

          -  Subjects with a history of seizure

          -  Recent history of (within 12 months) or strong potential for alcohol or substance
             abuse.

          -  Participation in a clinical study with exposure to any non-registered drug product
             within 30 days prior.

          -  Individual has a condition the Investigator believes would interfere with his or her
             ability to provide informed consent, comply with the study protocol, which might
             confound the interpretation of the study results or put the person at undue risk.
             Including subjects who are Bed or wheelchair-bound

          -  Untreated or unstable Hypothyroidism

          -  Subjects with active eating disorder including anorexia nervosa, bulimia, and/or
             obsessive compulsive eating disorders

          -  Pregnant, lactating, or unwilling to use adequate contraception during the duration of
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Gillam</last_name>
    <role>Study Director</role>
    <affiliation>Arthur Andrew Medical</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coagulation</keyword>
  <keyword>Circulatory Function</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Inflammatory response</keyword>
  <keyword>Blood Glucose</keyword>
  <keyword>Healthy vascular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

